Cord blood is the blood that remains inside the umbilical cord and the placenta after the baby has been delivered and the cord has been clamped and cut, and it is the same blood that was circulating between the baby and the placenta during pregnancy. The volume that can typically be collected after a term delivery is roughly fifty to one hundred and fifty millilitres, which is small enough to fit inside a single sealed collection bag and large enough to contain a clinically useful quantity of stem cells for the right indication. The reason this small volume of blood carries such disproportionate medical interest is that it is unusually rich in hematopoietic stem cells, which are the immature precursor cells that mature into every type of blood cell including the red blood cells that carry oxygen, the white blood cells that fight infection and the platelets that form clots, and which are the active ingredient in every bone marrow and stem cell transplant programme in modern medicine.

Cord blood stem cells share most of the clinical usefulness of bone marrow stem cells with two practical advantages and one significant limitation. The first advantage is that the cells are biologically younger and immunologically more tolerant than adult bone marrow cells, which means the match between donor and recipient can be slightly less perfect than for a bone marrow transplant and the transplant still succeed, and this matters particularly for patients from ethnic backgrounds that are under-represented in adult bone marrow donor registries. The second advantage is that the collection is painless, non-invasive and happens at a moment that would otherwise have no purpose — the cord and placenta are discarded after birth in any pregnancy that does not opt for collection. The significant limitation is volume — a single cord blood collection contains enough stem cells to transplant a child of up to roughly forty kilograms reliably but is often inadequate as a single source for transplanting an adult, which is why adult cord blood transplants frequently use two combined units or are combined with other stem cell sources.

A separate and lesser-known component of the cord is the Wharton's jelly mesenchymal stem cells contained in the gelatinous tissue around the cord blood vessels, and these are stored as cord tissue rather than as cord blood. Mesenchymal stem cells differ from hematopoietic stem cells in that they form connective tissue cells such as bone, cartilage and fat rather than blood cells, and their established clinical applications are at present limited to a small number of conditions with most use still at the research stage. Most Indian private banks offer cord tissue storage as an add-on to cord blood storage at an additional one-time cost of fifteen thousand to thirty thousand rupees.

The list of conditions for which a cord blood stem cell transplant is an established standard-of-care treatment is well defined and runs to roughly eighty individual diagnoses grouped into five broad categories. The largest category is the blood cancers, which includes the acute and chronic leukemias, the lymphomas including both Hodgkin and non-Hodgkin variants and the myelodysplastic syndromes, and these conditions together account for the majority of cord blood transplants performed worldwide and in India. The second category is the inherited disorders of red blood cells, with thalassemia major and sickle cell disease being the two that carry particular weight in the Indian context because of the high carrier frequency in several Indian communities and the cure that a successful stem cell transplant offers from a lifelong transfusion dependency. The third category is the primary immune deficiency disorders including severe combined immunodeficiency and Wiskott-Aldrich syndrome where the transplant rebuilds the missing immune system. The fourth category is the inherited bone marrow failure syndromes including Fanconi anaemia. The fifth category is a small number of inherited metabolic storage disorders where the transplanted stem cells supply the missing enzyme.

The list of conditions for which cord blood transplant remains at the research stage and is not yet a proven standard of care is significantly longer and includes cerebral palsy, autism spectrum disorder, type one diabetes, hearing loss, heart failure, traumatic brain injury, spinal cord injury and a long list of orthopaedic and neurological applications. Some of these research programmes are scientifically promising and may eventually yield approved treatments, but at present a family considering private cord blood banking on the basis of these speculative future applications is paying for a possibility rather than a proven indication, and the marketing material that lumps the established eighty conditions together with the speculative future list is misleading even when it is not technically dishonest.

The practical implication is that the headline marketing claim that cord blood can be used to treat any future disease the family might face is not accurate, and the more accurate framing is that cord blood is established for a specific list of conditions that is unlikely to grow dramatically in the next decade, that the probability of a given family ever drawing on its own banked sample is low even if a member is later diagnosed with a treatable condition because an unrelated bone marrow match is often available, and that the genuine medical case for private banking is strongest when there is an existing family history of one of the established indications.

The single most important decision an expecting family makes about cord blood is not whether to bank the sample at all but whether to bank it privately for the exclusive use of the family or to donate it publicly for use by any matched patient anywhere in the world. The two routes look superficially similar at the moment of collection because the cord blood is collected in the same way and travels to a similar laboratory, but they sit at opposite ends of the ethical and economic spectrum and serve different purposes.

A private family bank stores the cord blood sample exclusively for the donating family, charges the family for the collection kit, the processing and the annual storage at typical Indian rates of seventy thousand to one lakh fifty thousand rupees for a twenty-year package, and releases the sample only on the family's request and only for the family's use or for a first-degree relative such as a sibling. The advantage is that the sample is guaranteed to be available if a family member is later diagnosed with one of the established transplant indications and is a sufficient genetic match. The disadvantage is the cost and the low probability of ever drawing on the sample, with the estimated lifetime probability of a private cord blood sample being used by the family ranging from one in two hundred at the most generous estimate to one in twenty thousand at the most conservative estimate depending on which analysis you read and which assumptions about future medical applications you accept.

A public donor bank takes the cord blood sample as a free donation from the family, processes and stores it at no cost to the family, and adds it to a publicly accessible registry that any transplant centre in the world can search when looking for a match for an unrelated patient. The advantage is that the sample is much more likely to be used because the matching pool is the entire transplant-needing population rather than one family, and the donation contributes to the diversity of the global donor pool which is particularly important for Indian and South Asian patients who are under-represented in existing registries. The disadvantage from a private perspective is that the family gives up exclusive access to the sample, and if a family member is later diagnosed with a treatable condition the sample may already have been used by another patient. The major international paediatric and obstetric bodies including the World Health Organization, the American Academy of Pediatrics and the Royal College of Obstetricians and Gynaecologists have all reviewed this trade-off and recommend public donation over private storage for families without a specific medical indication, on the grounds that the public benefit is much greater than the marginal private benefit.

• LifeCell International is the largest Indian private family cord blood bank, headquartered in Chennai and operating since 2004, with a stored sample volume of roughly seven lakh units that makes it the market leader by a significant margin and a national network of collection-trained delivery hospitals across most Indian cities, with typical pricing of seventy thousand to one lakh fifty thousand rupees for a twenty-year storage package and easy monthly instalment options through partner finance companies.
• Cordlife India is the Indian arm of the Singapore-headquartered Cordlife Group and operates a private family bank with a smaller footprint than LifeCell but a long operating history and a comparable accreditation and pricing profile, with services available across most major Indian cities through partner delivery hospitals.
• CryoSave India, also branded as CryoBanks International in some markets, is another established private family bank with collection coverage across the major Indian cities and a similar service and pricing profile to the larger competitors.
• StemOne and Mother's Cell India are two smaller private banks that operate in selected Indian cities, and prospective parents choosing either should verify the current accreditation status, the operating history and the financial stability of the bank carefully because the long-term storage commitment of twenty years is only meaningful if the bank itself is still operating across that period.
• Jeevan Stem Cell Bank in Chennai is one of the best-established Indian public donor banks, takes cord blood donations free of charge from delivering families and releases samples to matched patients anywhere in the world, holds National Accreditation Board for Hospitals accreditation and partners with several Chennai-area delivery hospitals to make the donation pathway practical for local families.
• StemCyte India in Ahmedabad operates a similar public donor pathway, contributes its samples to international transplant registries and partners with Gujarat-area delivery hospitals to facilitate donation.
• All India Institute of Medical Sciences in Delhi runs a limited public cord blood programme that takes donations from selected delivering families at the AIIMS obstetric service and uses the samples within the AIIMS transplant programme and the linked public registry, with the programme being smaller in scale than the dedicated private and public bank operations but providing a public-sector option for Delhi-area families.

The cost of private cord blood banking in India is structured around three components that families should understand separately rather than as a single bundled headline figure, because the way each bank packages the components differs and the comparison across banks is only meaningful when the components are laid out individually. The first component is the one-time collection kit and processing fee which covers the sterile collection bag, the courier transport of the kit to the delivery hospital and back to the laboratory, the laboratory processing including the separation and counting of stem cells, the viral and bacterial screening tests required for a transplant-eligible sample and the initial cryopreservation, and which sits at roughly fifteen thousand to thirty thousand rupees at most major Indian banks.

The second component is the annual storage charge which covers the ongoing maintenance of the sample in liquid nitrogen at minus one hundred and ninety-six degrees Celsius, the periodic quality monitoring and the insurance against the loss of the sample due to equipment failure, and which sits at roughly three thousand to eight thousand rupees per year at most major Indian banks and which recurs for the life of the storage contract. The third component is the bundled long-term storage package, which combines the one-time fee and the annual charge into a single upfront payment for a fixed period of typically twenty years and which sits at roughly seventy thousand to one lakh fifty thousand rupees at most major Indian banks, and which is the headline price point that most family-facing marketing material quotes. Many banks offer easy monthly instalment options or no-cost equated monthly instalments through partner finance companies that spread the twenty-year package over twelve to thirty-six months of payments, which makes the headline number more accessible at the cost of a small finance charge in the no-cost EMI structures and a meaningful interest charge in the standard EMI structures.

Two further cost components apply in specific situations. The cord tissue storage add-on which preserves the Wharton's jelly mesenchymal stem cells separately from the cord blood adds a one-time charge of fifteen thousand to thirty thousand rupees on top of the cord blood package. And the eventual retrieval and shipping of the sample to a transplant centre if it is ever needed carries a separate charge of typically twenty to fifty thousand rupees that is paid at the time of retrieval rather than included in the storage package. Public donor banking carries no cost to the family for any of these components.

• Enrolment with the chosen cord blood bank typically happens between twenty-eight and thirty-two weeks of pregnancy, with the family completing a medical history questionnaire that screens for hereditary conditions, infectious disease risk factors and any contraindications to donation, signing the consent paperwork that authorises the collection and the storage, and paying the initial collection kit and processing fee or the first instalment of the bundled package.
• The bank dispatches the sterile collection kit by courier to the family's chosen delivery hospital ahead of the expected date of delivery, with a label that identifies the kit clearly to the labour ward staff and instructions for use that the family is encouraged to discuss with the obstetrician and the labour ward team in advance so that the collection is not delayed in the moments after birth by confusion about the protocol.
• At the time of delivery, after the baby has been born and the cord has been clamped and cut, the doctor or midwife inserts a needle into the umbilical vein in the section of cord still attached to the placenta and allows the cord blood to drain into the collection bag by gravity over one to two minutes, with the collection happening entirely on the placenta side of the cut and without any contact with the baby, and with no risk or discomfort to the baby. The collection works for both vaginal and cesarean deliveries with minor procedural adjustments.
• The labelled and sealed collection bag is couriered to the bank's central laboratory within twenty-four hours of collection at a temperature-controlled transport that preserves the viability of the cells, with the laboratory typically receiving samples from across India through a dedicated cold-chain courier partnership.
• On arrival at the laboratory the sample is processed to separate and concentrate the stem cell fraction, is tested for transmissible infections including HIV, hepatitis B and C, syphilis, cytomegalovirus and a panel of other agents required for a transplant-eligible sample, is counted to confirm an adequate stem cell dose, and is cryopreserved in liquid nitrogen at minus one hundred and ninety-six degrees Celsius in a sealed cryobag with a unique identification code that is then logged in the bank's database against the family's account.
• The sample remains in liquid nitrogen storage for the duration of the storage contract, with viability documented to roughly twenty years in published studies and research suggesting that meaningful viability extends significantly beyond that period, with the bank carrying out periodic quality monitoring and providing the family with annual statements confirming that the sample remains intact.

• A family with a known family history of thalassemia major, sickle cell disease, leukemia, lymphoma, an inherited immune deficiency or one of the other established cord blood transplant indications is the clearest case for private banking, because the genuine medical possibility of the sample being needed for the new baby's sibling or for the baby themselves is meaningfully higher than in the general population and the cost of banking is in proportion to the potential clinical benefit.
• Parents from genuinely different ethnic backgrounds where the baby's tissue type is likely to be a rare combination that would be difficult to match through an existing public donor registry are another reasonable case for private banking, because the baby's own siblings are the most likely source of a future match if it is ever needed and a banked sample from this baby may be the practical option for a future sibling diagnosis.
• A twin pregnancy is sometimes presented as a case for private banking on the grounds that two samples can be banked together and that each twin is a likely tissue match for the other, although the same logic applies equally to public donation if the family has no specific medical indication and the cost remains a real consideration for two simultaneous storage packages.
• A family in which the first child has already been diagnosed with a condition that is treatable by a stem cell transplant from a matched sibling donor is a strong case for private banking of the next baby's cord blood, because the cord blood sample may be the practical source for the older child's treatment if the new baby is a tissue match and the alternative is a longer search through public registries.
• A family without any of these factors who is considering private banking primarily on the basis of the marketing pitch around speculative future applications in cerebral palsy, autism, type one diabetes or general regenerative medicine is in the territory where the evidence is weakest and where the cost is least proportionate to the realistic medical benefit, and is the situation in which the World Health Organization and the American Academy of Pediatrics recommendation of public donation over private storage applies most clearly.

The ethical landscape around cord blood banking is shaped by a long-running tension between the genuine clinical usefulness of cord blood stem cells in an established list of conditions and the aggressive private-bank marketing that often overstates the likelihood that a given family will ever draw on its own banked sample. The major international paediatric and obstetric bodies including the World Health Organization, the American Academy of Pediatrics, the Royal College of Obstetricians and Gynaecologists and the European Group on Ethics in Science and New Technologies have all reviewed the evidence and reached broadly the same conclusion — that public donor banking is the preferred default for families without a specific medical indication because it maximises the public benefit of a small number of donated samples, and that private banking is appropriate for the smaller group of families with a genuine medical reason and is otherwise an expensive form of biological insurance with a low realistic payout.

Marketing material from Indian private banks is regulated under the general advertising standards code rather than by a dedicated cord blood advertising standard, which means the marketing claims a prospective family encounters in brochures, on parenting websites and through hospital-partnered counselling sessions vary widely in their accuracy and their tone. The most common areas where marketing material overstates the case are the lumping of the established eighty conditions with the speculative research-stage applications into a single headline claim that cord blood can be used to treat over eighty conditions including most chronic diseases, the framing of the probability of personal use in terms that emphasise the larger end of the wide estimate range, and the framing of the storage charge as a small monthly payment that downplays the significant cumulative cost over twenty years. A prospective family should read marketing material critically and should ask for the specific evidence behind any claim that does not match the framing of the major international paediatric and obstetric bodies.

The regulatory backdrop in India is structured around the Drug Controller General of India which licenses cord blood banks under the Drugs and Cosmetics Rules, the Central Drugs Standard Control Organisation which oversees the licensing process, and the National Accreditation Board for Hospitals and Healthcare Providers which provides voluntary accreditation that signals a higher quality standard. The American Association of Blood Banks accreditation is a similar voluntary international standard that some Indian banks hold. A prospective family should verify that a bank holds a current Drug Controller General of India licence at the very minimum, and should preferentially choose a bank that also holds NABH or AABB accreditation as a signal of higher quality. Avoid any bank that cannot produce a current licence on request.

Delayed cord clamping is the modern obstetric practice of waiting sixty to one hundred and eighty seconds after the birth of the baby before clamping and cutting the umbilical cord, which allows an additional placental transfusion of blood from the placenta to the baby in the minutes after birth. The World Health Organization recommends delayed cord clamping for all babies including those born by cesarean section on the grounds that the additional placental transfusion improves the baby's iron stores meaningfully for the first six months of life, reduces the rate of iron deficiency anaemia in infancy which is a particular concern in the Indian context where iron deficiency is widespread, and provides the baby with an additional dose of the baby's own stem cells through the natural physiological route. Delayed cord clamping is the new default in most modern Indian obstetric units and is the practice that obstetricians will recommend unless there is a specific reason to clamp early.

The practical tension with cord blood banking is that delayed cord clamping reduces the volume of blood that remains in the cord and placenta to be collected for banking, with the reduction in volume being broadly proportional to the duration of the delay. A full sixty to one hundred and eighty second delay can reduce the bankable cord blood volume by twenty to fifty percent, which may bring a borderline collection below the minimum stem cell dose required for a transplant-eligible sample and may invalidate the collection for banking purposes. The two practices are therefore not strictly incompatible but they do trade off against each other, and a family that is committed to both delayed cord clamping and cord blood banking needs to make an informed choice about the priority.

The conversation to have with the obstetrician before labour begins covers three options. The first option is to accept a shorter delayed clamp window of perhaps thirty seconds rather than the full sixty to one hundred and eighty seconds, which captures most of the iron-stores benefit of delayed clamping while preserving a larger bankable cord blood volume. The second option is to accept the full delayed clamp recommended by the World Health Organization and to accept the smaller bankable sample as a consequence, recognising that the sample may still be adequate for many transplant indications and that the iron-stores benefit of full delayed clamping is well established. The third option is to clamp early in order to maximise the bankable cord blood volume, which is the older practice and which is now generally only chosen when there is a strong specific reason for cord blood banking such as a known family history of an established transplant indication.

• Verify the bank's accreditation status before committing, with the minimum being a current Drug Controller General of India licence under the Drugs and Cosmetics Rules and the preferred signal of higher quality being either National Accreditation Board for Hospitals and Healthcare Providers accreditation or American Association of Blood Banks accreditation. Ask to see the current accreditation certificate rather than accepting a verbal assurance, and verify any claim independently through the relevant accreditation body's public register.
• Check the operating history and continuity of the bank, because a twenty-year storage commitment is only meaningful if the bank is still operating and still maintaining its liquid nitrogen storage at the end of that period, with banks that have been operating continuously for fifteen or twenty years offering more reassurance on this dimension than newer entrants regardless of pricing.
• Ask about the sample volume the bank has in storage and the laboratory throughput, with larger banks typically having more robust quality processes, better cryopreservation infrastructure and stronger financial stability than smaller competitors.
• Ask about the quarantine and infection screening policy that the bank applies to incoming samples, with a responsible bank running a full panel of viral and bacterial screening tests on every sample at the time of processing and maintaining the quarantine until all results are clear before adding the sample to the main storage facility.
• Ask about the insurance or replacement guarantee that the bank offers if the sample fails quality release at the time of transplant, with the best banks offering a written guarantee that they will compensate the family or pay for an alternative stem cell source if a stored sample is found to be unusable when the family eventually needs it.
• Ask for a written breakdown of all cost components including the one-time collection and processing fee, the annual storage charge if applicable, the bundled long-term package price, the cord tissue add-on if relevant and the eventual retrieval and shipping charge, with no hidden fees and with the written quote being valid for a defined period rather than offered verbally and changed later.
• Avoid any bank that pressures you to sign immediately, that makes claims about cord blood curing conditions that are not on the established eighty-condition list, or that cannot produce a current Drug Controller General of India licence on request, regardless of how attractive the pricing or the location appears.

• What is your hospital's policy on cord blood collection and which private and public banks does the hospital partner with for the collection process, because some hospitals have established relationships with specific banks that streamline the practical logistics and others have no formal partnership and require the family to coordinate the collection independently with the chosen bank.
• Can the hospital accommodate both delayed cord clamping and cord blood banking in the same delivery, and if so what is the typical compromise on the duration of the delayed clamp that the obstetric team recommends to balance the two practices, because this is a clinical judgement that varies between obstetricians and that should be agreed in advance rather than negotiated in the moment after the baby is born.
• What is the obstetrician's personal recommendation given the family's medical history, ethnic background and other relevant factors, with the obstetrician's view often being more measured and more individualised than the marketing material from any particular bank and being a useful counterpoint to the sales pitch that the family is otherwise encountering.
• What is the realistic probability that a sample banked privately would actually be used by the family in the foreseeable future, with the answer typically being one in two hundred to one in twenty thousand for a family without a specific medical indication and being meaningfully higher for a family with a known family history of an established transplant indication.
• If the family decides on public donation rather than private banking, what is the practical pathway at this hospital and which public bank should the family contact in advance to arrange the donation, because public donation requires advance coordination with a partner bank in the same way that private banking does and is not something that can be arranged in the moments after the baby is born.